Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2019-09-29 Regulatory Filings
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Sobi stärker position inom hemofili med potentiell veckovis behandling av hemofili A
Regulatory Filings Classification · 99% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and is dated September 29, 2019. It announces a significant business development: Sobi exercising an early option to expand its agreement with Sanofi regarding the development and commercialization of BIVV001, a hemophilia A treatment. It details financial considerations (payments, royalties) and clinical progress. This type of announcement, detailing strategic business moves, financing implications, and partnership updates, fits best under 'Capital/Financing Update' (CAP) or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure without a better fit. However, since it explicitly discusses exercising an option, making a $50M payment, and structuring future royalties related to development and commercialization rights, it strongly aligns with financing and capital structure changes related to a specific asset. Given the options, 'Capital/Financing Update' (CAP) is the most precise fit for an announcement detailing the financial terms of acquiring/expanding development rights for a drug candidate. It is not a formal regulatory report like 10-K or IR, nor is it a simple earnings release (ER).
2019-09-29 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by 'EdgePoint Investment Group Inc' in 'Swedish Orphan Biovitrum AB (publ)'. Specifically, it shows the 'Before the transaction' and 'After the transaction' share quantities and voting rights, noting the 'Reason for major shareholding notification Buy'. This structure, focusing on crossing ownership thresholds (10% limit mentioned), directly corresponds to the definition of a Major Shareholding Notification. Therefore, the correct classification is MRQ.
2019-08-30 English
Sobi completes acquisition of emapalumab and related assets
M&A Activity Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and details the completion of an acquisition (Sobi completes acquisition of emapalumab and related assets). This type of announcement, concerning corporate transactions like acquisitions, financing, or major asset changes, typically falls under Capital/Financing Update (CAP) or, more broadly, a significant corporate event announcement. Since the text details the financing (debt-financed via new credit facilities) and the transfer of assets/IP related to a drug, it strongly aligns with the 'Capital/Financing Update' (CAP) definition, which covers fundraising, financing activities, or capital structure changes. While it is a press release, it is not a general regulatory filing (RNS) because it fits a more specific category related to corporate finance/transaction. It is not an Earnings Release (ER) or an Interim Report (IR). Given the focus on the financial consideration (CHF 515 M) and the debt financing used, CAP is the most appropriate classification.
2019-07-18 English
Sobi slutför förvärvet av emapalumab och relaterade tillgångar
M&A Activity Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces that Sobi has completed the acquisition of emapalumab and related assets. This transaction involves significant financial outlay (515 MCHF) and changes in corporate structure (replacing a license agreement with an acquisition). This type of announcement, detailing a major corporate transaction like an acquisition, falls under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were a general notice. However, since it details fundraising/financing activities related to the capital structure change (debt financing mentioned), CAP is the most specific fit among the provided options, as it relates to capital structure changes and financing activities. It is not an earnings release (ER), an interim report (IR), or a formal 10-K. Given the focus on the financing of the acquisition, CAP is appropriate.
2019-07-18 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter (Q2) of 2019. It includes detailed financial tables (revenue, gross profit, EBITA, EPS), a CEO statement, a business review, and a detailed financial review section. It contains substantive financial data and analysis for a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report (IR). H1 2019
2019-07-17 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the second quarter (Kv2) of 2019, containing detailed financial tables (income statement, revenue by segment), management commentary ('Vd har ordet'), and operational reviews (Haematology, Immunology, R&D). It provides actual financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2019
2019-07-17 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.